Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.42 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26788238 | 0.90 | PTGDR2 (0.51) | PTGDR2SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL20103421 | 0.84 | PTGDR2 (0.40) | PTGDR2FFAR1MTNR1A | |
| SCHEMBL29003896 | 0.83 | HTR2C (0.49) | PTGDR2SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL27879994 | 0.80 | CREBBP (0.41) | CAMKK1CAMKK2 | |
| SCHEMBL1148370 | 0.79 | NPC1 (0.56) | PTGDR2MTNR1A | |
| SCHEMBL7028623 | 0.79 | NPC1 (0.47) | PTGDR2SMN1; SMN2 | |
| SCHEMBL20103517 | 0.79 | FFAR1 (0.51) | PTGDR2FFAR1 | |
| SCHEMBL21644868 | 0.79 | FFAR1 (0.51) | PTGDR2FFAR1 | |
| SCHEMBL20103513 | 0.79 | FFAR1 (0.51) | PTGDR2FFAR1 | |
| SCHEMBL31638753 | 0.79 | PTGDR2 (0.47) | PTGDR2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | PTGDR2 208/4885SMN1; SMN2 4068/4885FFAR1 16/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | PTGDR2 208/4885SMN1; SMN2 4068/4885FFAR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.